Clinical trials
Immune System Diseases clinical trials
Below are recruiting immune system diseases clinical trials, each written for real people, not researchers. We’re tracking 207 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07063199RecruitingPhase 2
Anti-CD38 antibody for older adults with hard-to-treat ITP
This trial tests an investigational antibody (anti-CD38) for older adults with ITP that hasn't improved with standard treatments. The goal is to see if this antibody can safely raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 60 years+ - NCT07297563RecruitingPhase 2
Anti-CD38 antibody vs rituximab for hard-to-treat ITP
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07362238RecruitingPhase 2
Daratumumab vs Rituximab for pediatric ITP
This study compares daratumumab to rituximab for children with primary immune thrombocytopenia (ITP) that hasn't improved with steroids. The goal is to find a better treatment to raise platelet counts and reduce bleeding risk.
TianjinAges 6–18 - NCT05995054RecruitingPhase 2
Obinutuzumab for chronic ITP that hasn't responded to steroids
This trial tests a drug called obinutuzumab for people with chronic ITP (low platelets) who haven't gotten better with steroids. The goal is to see if it can safely raise your platelet count.
TianjinAges 18 years+ - NCT07333313Recruiting
Study of oral medicine and probiotics for kidney disease in diabetes
This trial tests if an oral medication that absorbs toxins plus probiotics can reduce inflammation and slow kidney damage in people with diabetes-related kidney disease (DKD). It may help those with mild to severe kidney function loss.
Taipei, TaiwanAges 20 years+ - NCT07173621Enrolling by invitation
Comparing a wound-healing gel to standard care after thyroid or parathyroid surgery
This study compares a special wound-healing gel (called AMNIOEFFECT) with standard care after thyroid or parathyroid surgery. The goal is to see if the gel helps your incision heal better.
Sarasota, FloridaAges 18 years+ - NCT06094881RecruitingPhase 2
Obinutuzumab for teens with immune thrombocytopenia
This trial tests a drug called obinutuzumab for teens aged 12–18 with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if obinutuzumab can safely raise platelet counts in those who haven't responded well to steroids or other treatments.
TianjinAges 12–18 - NCT05036707RecruitingPhase 1/Phase 2
Study how tick bites change immune responses
This study looks at how a person’s immune system responds after exposure to Ixodes (black-legged) tick bites. It aims to better understand the body’s early immune reaction after tick exposure, using blood tests and small skin samples.
Bethesda, MarylandAges 18–99 - NCT06776510RecruitingPhase 1/Phase 2
NAD for immune thrombocytopenia study
This trial tests if a substance called NAD can help adults with immune thrombocytopenia (ITP) whose platelet levels stay low even after standard treatments. ITP is a condition where the immune system attacks platelets, causing easy bruising and bleeding. The study aims to see if NAD can safely raise platelet counts.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07626606Recruiting
Gut Health and Rotavirus Vaccine Response in Adults
This study examines how the health of your digestive system affects how well your body responds to an oral rotavirus vaccine (a vaccine given by mouth to protect against rotavirus infection). You'll have two endoscopy procedures—a camera test to look inside your digestive tract—and provide samples to help researchers understand this connection.
Lusaka, Lusaka ProvinceAges 18–50 - NCT05437328RecruitingPhase 1/Phase 2
CAR-T treatment for GD2/CD56 tumors that cannot be removed
This early-phase study tests a lab-made cell therapy (GD2/CD56 CAR-T) for cancers that have spread or come back and cannot be removed with surgery. It’s for people whose tumor tissue shows GD2 and/or CD56 on special lab tests, and it aims to control the cancer by targeting those tumor markers.
Shenzhen, GuangdongAges 1–75 - NCT05437341RecruitingPhase 1/Phase 2
CAR-T cell therapy for PSMA/CD70 tumors
This trial tests a lab-made immune cell treatment (CAR-T) designed to attack tumors that have specific markers called PSMA and/or CD70. It’s for people whose cancer has spread and can’t be fully removed with surgery, and it looks at safety and early signs of effectiveness.
Shenzhen, GuangdongAges 1–75 - NCT05438368RecruitingPhase 1/Phase 2
CAR-T therapy for tumors with GD2 or CD70 markers
This early-phase study tests a lab-made immune cell treatment (CAR-T) that targets tumor markers called GD2 and CD70. It is for people whose cancer has spread or returned and cannot be removed by surgery, to see if the treatment can work and how safe it is.
Shenzhen, GuangdongAges 1–75 - NCT06435897RecruitingPhase 1/Phase 2
MSC and CAR-T cell therapy for autoimmune disease
This trial tests a new treatment using a combination of two types of immune cells (MSCs and CAR-T cells) to calm the immune system and treat autoimmune diseases. It may help people whose autoimmune condition is not well controlled with current medications.
Shenzhen, GuangdongAges 18–75 - NCT05927233RecruitingPhase 4
Methylprednisolone in children after open-heart surgery
This trial tests whether giving methylprednisolone (a steroid medicine) can lower the body’s inflammatory response in children during the first day after congenital open-heart surgery. It may help reduce harmful inflammation and improve recovery for some children undergoing their first surgery.
Karachi, SindhAges 1 month–18 years - NCT06947460RecruitingPhase 1/Phase 2
CAR-T cell therapy for resistant lupus, sclerosis, and Sjögren's lung disease
This trial tests a special immune cell therapy (CAR-T cells targeting CD19 and BCMA) for people with lupus nephritis, systemic sclerosis, or Sjögren's-related lung blood vessel disease that hasn't improved with usual treatments. The goal is to see if this one-time cell infusion can calm the overactive immune system and improve symptoms.
Beijing, China,BeijingAges 10–65 - NCT06052436RecruitingPhase 1/Phase 2
Treg cell therapy for COVID-19 and acute respiratory distress
This trial tests a new cell therapy using Treg cells from thymic tissue to calm an overactive immune response in severe COVID-19 and ARDS. It aims to improve breathing and reduce inflammation.
Madrid, MadridAges 18–65 - NCT06197581Recruiting
Safety of Radiation with Modern Breast Cancer Drugs
This study checks if giving certain modern breast cancer drugs at the same time as radiation is safe. It's for women who need radiation and are also taking one of these drugs: capecitabine, a CDK4/6 inhibitor, a PARP inhibitor, immunotherapy, or a HER2 inhibitor.
Beijing, Beijing MunicipalityAges 18–70 - NCT06658834RecruitingPhase 2
Romiplostim for newly diagnosed ITP in adults
This trial tests a medicine called romiplostim (Nplate) as a first treatment for adults newly diagnosed with ITP. It aims to see if it can safely raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07212335RecruitingEarly Phase 1
Stem cells for low blood counts after CAR-T
This trial tests if umbilical cord stem cells can help restore low blood counts in people with leukemia, lymphoma, or myeloma who still have low blood cell levels three weeks after CAR-T therapy. It aims to improve recovery and reduce infection or bleeding risks.
TianjinAges 18 years+ - NCT07352332Recruiting
Immune study of a new treatment for hard-to-treat lupus in children
This study looks at how a treatment called CD3xCD19 BiTE affects the immune system of children with lupus that hasn't gotten better with standard medicines. It uses leftover blood samples to learn more about why some children don't respond to usual treatments.
HangzhouAges 5 years+ - NCT06992128RecruitingPhase 2
Romiplostim plus steroids for newly diagnosed ITP
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07543380RecruitingPhase 3
RSV vaccine safety and immune response in high-risk adults
This study tests a new RSV vaccine designed to protect adults with chronic health conditions from severe RSV disease (a respiratory infection). Researchers will monitor how safe the vaccine is and how well your immune system responds to it.
Tsuchiura, IbarakiAges 18–59 - NCT07362199RecruitingPhase 2
New combo treatment for chronic ITP
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+
Hear when a new Immune System Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immune system diseases?
- Yes. Clin2 currently lists 207 recruiting immune system diseases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immune system diseases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immune system diseases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.